Pharmacosmos A/S
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Pharmacosmos A/S - overview
Established
1965
Location
-, -, Denmark
Primary Industry
Pharmaceuticals
About
Founded in 1965 by Henry Christensen and based in Denmark, Pharmacosmos A/S operates as a pharmaceutical company that develops and manufactures drugs for treating iron deficiency anaemia. In November 2021, Pharmacosmos A/S acquired AbFero Pharmaceuticals, Inc. from UF Innovate Ventures, Longwall Ventures, and DeepWork Capital for approximately USD 225 million, including upfront payments, regulatory and commercial milestones, and royalties. As of 2024, the company is led by its CEO, Tobias S.
Christensen, and has affiliates in the US, China, UK, Ireland, Germany, Sweden, and Norway. Its products are marketed in more than 80 countries across the world. The company offers a range of products under brand names, including Monofer®, CosmoFer®, Diafer®, Uniferon®, and Pentahibe®. These products are designed to address iron deficiency in various patient populations, including those with chronic kidney disease, heart failure, or inflammatory bowel disease.
The firm’s portfolio includes injectable and oral iron therapies tailored to meet diverse medical needs. Pharmacosmos also extends its expertise to the veterinary field, offering specialized iron products for animals as well as carbohydrates.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.pharmacosmos.com/
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Pharmacosmos A/S - timeline of key events
Pharmacosmos A/S - financials
| Fiscal Year Ended | Apr 30, 2014 | Apr 30, 2015 | Apr 30, 2016 | Apr 30, 2017 | Apr 30, 2018 | Apr 30, 2019 | Apr 30, 2020 | Apr 30, 2021 | Apr 30, 2022 | Apr 30, 2023 | Apr 30, 2024 | Apr 30, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | 448,039,126 | 616,747,000 | 613,893,000 | 713,209,000 | 748,670,000 | 849,341,000 | 1,321,487,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | 37.7% | (0.5%) | 16.2% | 5.0% | 13.4% | 55.6% | - | - | - |
| EBITDA (USD) | 57,138,790 | 164,066,477 | 198,087,128 | 267,962,000 | 196,137,000 | 204,411,000 | 210,383,000 | 23,664,000 | 219,355,000 | - | - | - |
| Operating Income (USD) | 13,170,621 | 104,797,372 | 134,006,748 | 195,539,000 | 127,079,000 | 111,613,000 | 92,064,000 | (71,421,000) | 124,286,000 | - | - | - |
| Operating Margin | - | - | 29.9% | 31.7% | 20.7% | 15.6% | 12.3% | (8.4%) | 9.4% | - | - | - |
| % EBITDA Margin | - | - | 44.2% | 43.4% | 31.9% | 28.7% | 28.1% | 2.8% | 16.6% | - | - | - |
| NET Income (USD) | 6,168,543 | 81,142,658 | 102,693,508 | 158,715,000 | 69,125,000 | 102,068,000 | 56,457,000 | (136,005,000) | 170,038,000 | - | - | - |
| % Net Margin | - | - | 22.9% | 25.7% | 11.3% | 14.3% | 7.5% | (16.0%) | 12.9% | - | - | - |
Pharmacosmos A/S - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.